Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Roivant Sciences Ltd. (ROIV : NSDQ)

• Company Description    Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK. Number of Employees: 721

• Price / Volume Information    Yesterday's Closing Price: $41.48 Daily Weekly Monthly 20 Day Moving Average: 8,135,123 shares Shares Outstanding: 722.32 (millions) Market Capitalization: $29,961.96 (millions) Beta: 1.12 52 Week High: $42.50 52 Week Low: $13.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.67% 18.51% 12 Week 36.40% 33.52% Year To Date 91.15% 70.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7th Floor 50 Broadway - LONDON,X0 SW1H 0DB GBR ph: 44-20-7400-3347 fax: - keyur.parekh@roivant.com https://roivant.com

• General Corporate Information    Officers Matthew Gline - Chief Executive Officer and Director Mayukh Sukhatme - President and Chief Investment Officer Richard Pulik - Chief Financial Officer Jennifer Humes - Chief Accounting Officer Keith Manchester - Director Peer Information Roivant Sciences Ltd. (CORR.) Roivant Sciences Ltd. (RSPI) Roivant Sciences Ltd. (CGXP) Roivant Sciences Ltd. (BGEN) Roivant Sciences Ltd. (GTBP) Roivant Sciences Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G76279101 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 722.32 Most Recent Split Date: (:1) Beta: 1.12 Market Capitalization: $29,961.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.00 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 36.35% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.09 Price/Cash Flow: - Price / Sales: 3,977.96 EPS Growth vs. Year Ago Period: -50.00% vs. Previous Quarter: 2.17% Sales Growth vs. Year Ago Period: -33.55% vs. Previous Quarter: -42.78% ROE 06/30/26 - -22.94 03/31/26 - -20.54 12/31/25 - -19.04 ROA 06/30/26 - -21.53 03/31/26 - -19.43 12/31/25 - -18.15 Current Ratio 06/30/26 - 16.72 03/31/26 - 18.37 12/31/25 - 30.66 Quick Ratio 06/30/26 - 16.72 03/31/26 - 18.37 12/31/25 - 30.66 Operating Margin 06/30/26 - -15,224.35 03/31/26 - -12,365.73 12/31/25 - -7,076.27 Net Margin 06/30/26 - -3,534.96 03/31/26 - -3,629.19 12/31/25 - -6,079.94 Pre-Tax Margin 06/30/26 - -3,848.65 03/31/26 - -3,203.12 12/31/25 - -6,925.09 Book Value 06/30/26 - 6.81 03/31/26 - 7.35 12/31/25 - 7.01 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©